The obvious solution is to replace or artificially provide patients’ NK cells with priming signals. This converts an NK cell that needs two signals from a cancer cell to an NK cell that needs only triggering signals to initiate cancer killing. More importantly, it eliminates a major mechanism by which cancer cells evade a patient’s immune system.
This obvious solution is not simple, but it is exactly what INmune Bio is doing. INmune Bio is developing an S1 therapeutic product that can be infused into the patient to move the resting NK cells to S2. We call this product INKmune™.